FDA approves new targeted treatment for relapsed or refractory acute myeloid leukemia - FDA Press Releases

The U.S. Food and Drug Administration today approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. The drug is approved for use with a companion diagnostic, the RealTime IDH2 Assay, which is used to detect specific mutations in the IDH2 gene in patients with AML.

from Food and Drug Administration--Press Releases http://ift.tt/2vjzQ2v
via IFTTT